UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
126.20
+0.26 (+0.21%)
At close: 4:00PM EDT

126.08 -0.12 (-0.10%)
After hours: 5:29PM EDT

Stock chart is not supported by your current browser
Previous Close125.94
Open126.00
Bid125.97 x 1400
Ask142.00 x 800
Day's Range124.42 - 127.74
52 Week Range100.57 - 152.55
Volume263,200
Avg. Volume344,039
Market Cap5.498B
Beta1.15
PE Ratio (TTM)7.79
EPS (TTM)16.20
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est124.90
Trade prices are not sourced from all markets
  • United Therapeutics In-Licenses Rights to IPF Candidate
    Zacks8 hours ago

    United Therapeutics In-Licenses Rights to IPF Candidate

    United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.

  • PR Newswire13 hours ago

    United Therapeutics Corporation To Host Science Day 2018

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on ...

  • PR Newswire2 days ago

    Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate

    SAN DIEGO and SILVER SPRING, Md., Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). "We are excited to partner with United Therapeutics because of its culture of integrity, level of commitment, and expertise in pulmonology and drug-device combinations. SM04646, a Wnt pathway inhibitor, is currently undergoing a phase 1 clinical trial.

  • See what the IHS Markit Score report has to say about United Therapeutics Corp.
    Markit3 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • S Spotlight On United Therapeutics Corporation’s (NASDAQ:UTHR) Fundamentals
    Simply Wall St.4 days ago

    S Spotlight On United Therapeutics Corporation’s (NASDAQ:UTHR) Fundamentals

    United Therapeutics Corporation (NASDAQ:UTHR) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...

  • United Therapeutics makes another real estate buy
    American City Business Journals5 days ago

    United Therapeutics makes another real estate buy

    United Therapeutics Corp. is buying up more real estate — and the Maryland biotech didn't go far to do it this time. United Therapeutics (NASDAQ: UTHR) has purchased 8808 Cameron St. in Silver Spring for $2.6 million. The two-story, 10,738-square-foot building’s two owners, Leadership Conference of Women Religious and Conference of Major Superiors of Men, have operated out of the space for years, according to Avi Halpert, vice president of real estate and construction for United Therapeutics.

  • Motley Fool10 days ago

    Is MannKind Corporation Stock a Buy?

    A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool10 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Big news lit a fire under these biotech stocks this week. But can their momentum continue?

  • RANKED: Best Places To Work - Extra-Large Companies
    American City Business Journals12 days ago

    RANKED: Best Places To Work - Extra-Large Companies

    Headquarters: Chapel Hill  Local employees: 397 Founded: 1984  Industry: Clinical research CEOs: Laura Helms Reece and Russ Helms List the major accomplishments at your workplace that propelled your company to being one of the Best Places to Work in 2018. Rho’s focus on teamwork, collaboration and innovation promotes an environment where employees feel valued. Through Rho24, employees are given the platform to create innovative solutions to areas that have been identified as needing improvement.

  • Motley Fool12 days ago

    A New Deal Moves MannKind Back From the Brink

    A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.

  • The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
    Zacks12 days ago

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

  • See what the IHS Markit Score report has to say about United Therapeutics Corp.
    Markit12 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    United Therapeutics Corp NASDAQ/NGS:UTHR

  • InvestorPlace13 days ago

    New Development Partnership Could Pay Off Big for MannKind Stock

    After spending much of 2017 in a downtrend, MannKind (NASDAQ:MNKD) lit up on the stock market and closed above $2.00 a share on Sept. 4 for the first time since June. The company announced that it would collaborate with United Therapeutics (NASDAQ:UTHR) on treprostinil, an investigational drug for the treatment of pulmonary arterial hypertension. The cash infusion from the deal is just what MannKind needed.

  • MannKind Stock Up on Licensing Deal With United Therapeutics
    Zacks13 days ago

    MannKind Stock Up on Licensing Deal With United Therapeutics

    MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

  • Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
    Zacks13 days ago

    Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

    Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

  • United Therapeutics Enters into a Collaboration with MannKind
    Market Realist14 days ago

    United Therapeutics Enters into a Collaboration with MannKind

    United Therapeutics and MannKind’s collaboration is for an investigational treprostinil dry powder that is presently in clinical trials. According to the terms of the agreement, United Therapeutics (UTHR) is responsible for the development, regulatory activities, and commercialization of this dry powder.

  • Why MannKind Stock Is Skyrocketing Today
    InvestorPlace14 days ago

    Why MannKind Stock Is Skyrocketing Today

    The good news for MNKD stock comes in the form of an agreement to have it manufacture a dry powder formulation of treprostinil. This is a drug that is currently in testing for treating pulmonary arterial hypertension. The deal will have MannKind acting as the manufacturer for clinical supplies of the drug and its initial commercial run. For its efforts, the company is getting an upfront payment of $45 million.

  • Why MannKind Corporation Stock Is Skyrocketing Today
    Motley Fool14 days ago

    Why MannKind Corporation Stock Is Skyrocketing Today

    Shares are soaring following the company's announcement of a new partnership agreement. Here's what investors need to know.

  • Benzinga14 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Nike Inc (NYSE: NKE ) stock was trading lower by nearly ...

  • Markit14 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • American City Business Journals14 days ago

    United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery

    Under the deal with MannKind Corp., Silver Spring's United Therapeutics will be responsible for global development, regulatory and commercial activities for the dry power formulation and inhalation delivery of treprostinil, the active ingredient in United Therapeutics' flagship product Remodulin.

  • CNW Group14 days ago

    Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

    VANCOUVER , Sept. 4, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today highlighted that United Therapeutics (UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.

  • United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?
    Zacks18 days ago

    United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?

    United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about United Therapeutics Corp.
    Markit19 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire19 days ago

    United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

    SILVER SPRING, Md. , Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) ("United Therapeutics") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: ...